Difference between revisions of "Vigilin"
m |
|||
(One intermediate revision by one other user not shown) | |||
Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
− | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
− | |||
− | |||
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
Line 48: | Line 46: | ||
| | | | ||
|- | |- | ||
− | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] |
Latest revision as of 12:01, 10 March 2015
Vigilin | |
---|---|
Substrate peptide name | Vigilin |
Synonyms | High density lipoprotein-binding protein
HDL-binding protein |
Determination type | In situ/In vitro |
Source | Homo sapiens |
Subcellular localization | Nucleus
Cytosol |
Swissprot ID | Q00341 |
Reactive glutamines | Not determined yet |
Reactive lysines | - |
Substrate sequence | |
Structure | 1VIG |
Surface accessibility | |
Disorder prediction | IUPred |
Reference | PMID:12799366 |
Notes | |